Investor Relations

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).

NASDAQ | AVEO (Common Stock)
$0.710.00
Stock chart for: AVEO.O.  Currently trading at $0.71 with a 52 week high of $1.15 and a 52 week low of $0.54.
03/23/17 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in Advanced RCCRead More
AVEO Reports Full Year 2016 Financial Results and Provides Business UpdateRead More
AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety ReviewRead More